Table 1.

Baseline rheumatoid arthritis patient characteristics.

		Ofatumumab
Characteristic		Placebo, n = 8	0.3 mg, n = 4	3 mg, n = 6	30 mg, n = 8	60 mg, n = 6	100 mg, n = 3	Total, n = 35
Age, yrs	Mean	51.4	55.8	49.0	52.8	60.2	46.0	52.8
Age, yrs	Range	31–71	34–69	22–72	30–63	53–78	38–53	22–78
Sex, n (%)	Female	7 (88)	4 (100)	5 (83)	7 (88)	6 (100)	2 (67)	31 (89)
Race, n (%)	Other^a	1 (13)	0	0	1 (13)	0	0	2 (6)
Race, n (%)	White	7 (88)	4 (100)	6 (100)	7 (88)	6 (100)	3 (100)	33 (94)
BMI	kg/m²	30.01	30.85	30.46	27.85	29.54	30.95	29.69
BMI	Mean SD	3.82	3.60	6.17	2.16	7.47	2.41	4.52
RF-positive, n (%)		7 (88)	1 (25)	3 (50)	6 (75)	2 (33)	2 (67)	21 (60)
Anti-CCP+	n (%)	4 (50)	2 (50)	3 (50)	7 (88)	3 (50)	2 (67)	21 (60)
MTX dose	Mean (mg/wk)	16.25	16.25	15.42	15.00	10.83	14.17	—
Prednisolone dose^b	Mean (mg/qd)	4.75	5.83	5.00	7.00	10.00	0	—
Prednisolone dose^b	n	4	3	1	5	2	0

↵^aAmerican Indian or Alaska native.
↵^bSummary of steroids for patients taking steroid (prednisolone equivalent). Anti-CCP: anticyclic citrullinated peptide; RF: rheumatoid factor; BMI: body mass index; MTX: methotrexate.